CD152 (CTLA-4) Antibody 14-1529-82 from Thermo Fisher Scientific

Product Specs
ItemCD152 (CTLA-4) Antibody
CompanyThermo Fisher Scientific
Price Pricing Info Supplier Page View Company Product Page
Catalog Number14-1529-82
Quantity100 µg
ApplicationsFlow Cytometry, Functional assay, Neutralization
Concentration0.5 mg/mL
Conjugate/TagUnconjugated
FormatPBS with 0.09% sodium azide; pH 7.2
ReactivityHuman, Rhesus Monkey
TargetCD152 (CTLA-4)
IsotypeIgG2a kappa
Clone14D3
HostMouse
NCBI Full Gene Namecytotoxic T-lymphocyte associated protein 4
NCBI Gene AliasesGRD4, CTLA-4, CELIAC3, CD, CD152, GSE, ALPS5, IDDM12
ClonalityMonoclonal
PurityAffinity chromatography
Storage Temperature4° C
Antibody TypePrimary
Storage4° C

Add to Compare List

Thermo Fisher Scientific

81 Wyman Street

Waltham, MA 02451

United States

Phone: 800-678-5599
Fax: 800-331-2286

Company Profile

Website: www.thermofisher.com

(1) The transcription factor IRF2 drives interferon-mediated CD8(+) T cell exhaustion to restrict anti-tumor immunityImmunityDecember 13, 2022Lukhele S, Rabbo DA, Guo M, Shen J, Elsaesser HJ, Quevedo R, Carew M, Gadalla R, Snell LM, Mahesh L, et al.AD2),Biolegend,Cat#344002; RRID:AB_2154067 Tm(169)-anti-human CTLA4 (Clone 14D3),ThermoFisher,Cat#14-152982; RRID:AB_467512 Er(170)-anti-human CD317 (Clone RS38E),Biolegend,Cat#348402; RRID:AB_10588013 Yb(171)-anti-human

(2) Mass cytometry immunostaining protocol for multiplexing clinical samplesSTAR protocolsSeptember 16, 2022Gadalla R, Boukhaled GM, Brooks DG, Wang BX.Biosciences,55568 CD45RA,BioLegend,304143 Helios,BioLegend,137202 Ki67,BioLegend,350523 T-bet,Fluidigm,3161014B CD45,Fluidigm,3089003B CD45,Fluidigm,3198001B CD28,BioLegend,302937 CD137,BioLegend,309802 CD86,BioLegend,555655 TIM3,BioLegend,345019 PKR,Novus Biologicals,Custom-made CD73,Fluidigm,3168015B CTLA4,Thermo Fisher Scientific,14-1529-82 CD39,BioLegend,328221 CD3,BioLegend,300443 CD303,BioLegend,354215 CD14,BioLegend,301802 CD27,BioLegend,302839 CD25,BioLegend,356102 PD1,Fluidigm,3165039D IL-10,BioLegend,501423 SOCS1,Millipore,04-002 PDL1,Fluidigm,3175008B HLA-DR,Fluidigm,307651 ICOS,BD Biosciences

(3) Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIVeLifeJuly 5, 2022Ma T, McGregor M, Giron L, Xie G, George AF, Abdel-Mohsen M, Roan NR.14-5825-82,CyTOF (1:25) Antibody,"CD152 (CTLA-4) Monoclonal Antibody(Mouse, Monoclonal)",Thermo Fisher,Cat# 14-1529-82,CyTOF (1:50) Commercial assay or kit,Lenti-X p24Gag Rapid Titer Kit,Takara,Cat# 632200, Commercial

(4) Human IL-10-producing B cells have diverse states that are induced from multiple B cell subsetsCell ReportsApril 19, 2022Marla C. Glass, David R. Glass, John-Paul Oliveria, Berenice Mbiribindi, Carlos O. Esquivel, Sheri M. Krams, Sean C. Bendall, Olivia M. Martinez(clone UCHT2) - 209 Bi,Biolegend,Cat # 300602 anti-CD152/CTLA4 (clone 14D3) - 160 Gd,Invitrogen,Cat # 14-1529-82 anti-IL17A (clone BL168) - 161 Dy,Fluidigm,Cat # 3161008B anti-IFNg (clone B27) - 168 Er,Fluidigm,Cat

(5) Cancer stem-like cells evade CD8(+)CD103(+) tumor-resident memory T (T(RM)) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor modelJournal for immunotherapy of cancerApril 1, 2022Corgnac S, Damei I, Gros G, Caidi A, Terry S, Chouaib S, Deloger M, Mami-Chouaib F.

(6) A blood atlas of COVID-19 defines hallmarks of disease severity and specificityCellMarch 3, 2022COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk., COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium..

(7) Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinomaCell reports. MedicineOctober 19, 2021Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, et al.RRID:AB_2714155" CD28 (CD28.2),Fluidigm,"Cat# 3160003B, RRID:AB_2868400" CTLA4 (14D3),ThermoFisher,"Cat# 14-1529-82, RRID:AB_467512" FoxP3 (PCH101),Fluidigm,"Cat# 3162011A, RRID:AB_2687650" CD45RO (UCHL1),Fluidigm,"Cat#

(8) Engineering advanced logic and distributed computing in human CAR immune cellsNature communicationsFebruary 4, 2021Cho JH, Okuma A, Sofjan K, Lee S, Collins JJ, Wong WW.

(9) Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosisAnnals of translational medicineDecember 1, 2020Ye LL, Peng WB, Niu YR, Xiang X, Wei XS, Wang ZH, Wang X, Zhang SY, Chen X, Zhou Q.

(10) Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLLGenome medicineMarch 18, 2020Wierzbinska JA, Toth R, Ishaque N, Rippe K, Mallm JP, Klett LC, Mertens D, Zenz T, Hielscher T, Seifert M, et al.

(11) Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate CancerScientific reportsJuly 23, 2019Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, Ness N, Ingebriktsen LM, Fassina A, Taskén KA, et al.

(12) CD103⁺ tumor-infiltrating lymphocytes predict favorable prognosis in patients with esophageal squamous cell carcinomaJournal of CancerJanuary 1, 2019Chu Y, Liao J, Li J, Wang Y, Yu X, Wang J, Xu X, Xu L, Zheng L, Xu J, et al.

(13) HDAC inhibition potentiates immunotherapy in triple negative breast cancerOncotargetDecember 26, 2017Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN.

(14) Transcription Factor IRF4 Promotes CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic InfectionImmunityDecember 19, 2017Man K, Gabriel SS, Liao Y, Gloury R, Preston S, Henstridge DC, Pellegrini M, Zehn D, Berberich-Siebelt F, Febbraio MA, et al.

(15) CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastasesCancer immunology, immunotherapy : CIINovember 1, 2017Paulsen EE, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, Busund LT, Bremnes RM, Donnem T.

(16) The transcription factor musculin promotes the unidirectional development of peripheral T_reg cells by suppressing the T_H2 transcriptional programNature immunologyMarch 1, 2017Wu C, Chen Z, Dardalhon V, Xiao S, Thalhamer T, Liao M, Madi A, Franca RF, Han T, Oukka M, et al.

(17) Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cellsThe Journal of allergy and clinical immunologyFebruary 1, 2017Chen HH, Händel N, Ngeow J, Muller J, Hühn M, Yang HT, Heindl M, Berbers RM, Hegazy AN, Kionke J, et al.

(18) Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infectionNature communicationsOctober 20, 2015Miles B, Miller SM, Folkvord JM, Kimball A, Chamanian M, Meditz AL, Arends T, McCarter MD, Levy DN, Rakasz EG, et al.

(19) High levels of soluble CTLA-4 are present in anti-mitochondrial antibody positive, but not in antibody negative patients with primary biliary cirrhosisPloS oneJanuary 1, 2014Saverino D, Pesce G, Antola P, Porcelli B, Brusca I, Villalta D, Tampoia M, Tozzoli R, Tonutti E, Alessio MG, et al.

(20) Residual methylprednisolone suppresses human T-cell responses to spleen, but not islet, extracts from deceased organ donorsInternational immunologyJuly 1, 2012Joffe M, Necula AS, Chand R, McWhinney BC, Krishnamurthy B, Loudovaris T, Goodman D, Thomas HE, Kay TW, Mannering SI.

Be the First to Write a Review!

Flow

Flow

CD152 (CTLA-4) Antibody from Thermo Fisher Scientific

Thermo Fisher Scientific

Citations (21)

Reviews

CD152 (CTLA-4) Antibody from Thermo Fisher Scientific

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map